MA49744A - TREATMENT METHODS FOR ACTIVE EOSINOPHILIC ESOPHAGITIS - Google Patents
TREATMENT METHODS FOR ACTIVE EOSINOPHILIC ESOPHAGITISInfo
- Publication number
- MA49744A MA49744A MA049744A MA49744A MA49744A MA 49744 A MA49744 A MA 49744A MA 049744 A MA049744 A MA 049744A MA 49744 A MA49744 A MA 49744A MA 49744 A MA49744 A MA 49744A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment methods
- eosinophilic esophagitis
- active eosinophilic
- active
- esophagitis
- Prior art date
Links
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 title 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/247—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762541242P | 2017-08-04 | 2017-08-04 | |
US201762561593P | 2017-09-21 | 2017-09-21 | |
EP18305252 | 2018-03-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA49744A true MA49744A (en) | 2020-06-10 |
Family
ID=63113646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA049744A MA49744A (en) | 2017-08-04 | 2018-08-03 | TREATMENT METHODS FOR ACTIVE EOSINOPHILIC ESOPHAGITIS |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3661551A1 (en) |
JP (2) | JP7417515B2 (en) |
KR (1) | KR20200035442A (en) |
CN (1) | CN111032084A (en) |
AU (1) | AU2018311981A1 (en) |
CA (1) | CA3071528A1 (en) |
IL (1) | IL272245B1 (en) |
MA (1) | MA49744A (en) |
MX (1) | MX2020001305A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117085122A (en) * | 2022-04-29 | 2023-11-21 | 中山康方生物医药有限公司 | Antibodies against human IL-4RA and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI634900B (en) * | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor |
WO2015061441A1 (en) * | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
EP3268032A1 (en) * | 2015-03-11 | 2018-01-17 | GlaxoSmithKline Intellectual Property Development Limited | Tslp binding proteins |
-
2018
- 2018-08-03 AU AU2018311981A patent/AU2018311981A1/en active Pending
- 2018-08-03 MX MX2020001305A patent/MX2020001305A/en unknown
- 2018-08-03 EP EP18750578.9A patent/EP3661551A1/en active Pending
- 2018-08-03 JP JP2020505844A patent/JP7417515B2/en active Active
- 2018-08-03 MA MA049744A patent/MA49744A/en unknown
- 2018-08-03 IL IL272245A patent/IL272245B1/en unknown
- 2018-08-03 CN CN201880050334.6A patent/CN111032084A/en active Pending
- 2018-08-03 KR KR1020207006346A patent/KR20200035442A/en active IP Right Grant
- 2018-08-03 CA CA3071528A patent/CA3071528A1/en active Pending
-
2023
- 2023-11-13 JP JP2023192683A patent/JP2024016237A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020001305A (en) | 2020-03-09 |
EP3661551A1 (en) | 2020-06-10 |
KR20200035442A (en) | 2020-04-03 |
JP2020529434A (en) | 2020-10-08 |
RU2020109331A3 (en) | 2021-12-28 |
JP7417515B2 (en) | 2024-01-18 |
JP2024016237A (en) | 2024-02-06 |
IL272245A (en) | 2020-03-31 |
CA3071528A1 (en) | 2019-02-07 |
RU2020109331A (en) | 2021-09-06 |
CN111032084A (en) | 2020-04-17 |
AU2018311981A1 (en) | 2020-02-20 |
IL272245B1 (en) | 2024-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45192A (en) | ASSOCIATION TREATMENT | |
DK3731772T3 (en) | SYSTEMS FOR THE TREATMENT OF DISEASE STATES AND DISORDERS | |
DK3516060T3 (en) | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF EYE DISEASE | |
MA46954A (en) | METHODS OF TREATING INFLAMMATORY CONDITIONS | |
MA40867A (en) | METHODS FOR THE TREATMENT OF FILOVIRIDAE VIRAL INFECTIONS | |
DK3448999T3 (en) | OLIGONUCLEOTIDES FOR TREATMENT OF EYE DISEASE | |
DK3364997T5 (en) | ASPARTOACYLASE GENE THERAPY FOR THE TREATMENT OF CANAVAN'S DISEASE | |
MA46062A (en) | TREATMENT WITH ASCAROSIDE FOR EOSINOPHILIC ESOPHAGITIS | |
MA45539A (en) | DIHYDROPYRANOPYRIMIDINES FOR THE TREATMENT OF VIRAL INFECTIONS | |
DK3386511T3 (en) | PROCEDURES FOR THE TREATMENT OF HUNTINGTON'S DISEASE | |
MA41028A (en) | METHODS AND FORMULATIONS FOR THE TREATMENT OF VASCULAR EYE PATHOLOGIES | |
MA47719A (en) | ESKETAMINE FOR THE TREATMENT OF DEPRESSION | |
MA53329A (en) | EPILEPSY TREATMENT METHODS | |
MA47504A (en) | COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS | |
DK3784103T3 (en) | Floor treatment machine | |
MA52216A (en) | TREATMENT METHODS FOR ULCERATIVE COLITIS | |
DK3393579T3 (en) | EYE TREATMENT SYSTEM | |
MA46524A (en) | BIPHENYL-SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEPHROPATHIES | |
MA47212A (en) | TREATMENT METHODS FOR NEUROLOGICAL DISORDERS | |
MA46353A (en) | WOMEN'S INFERTILITY TREATMENT METHODS | |
MA49576A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | |
ES2893126T8 (en) | Treatment methods for eye conditions | |
MA54860A (en) | MULTIPLE MYELOMA TREATMENT METHODS | |
MA47437A (en) | FUNGAL INFECTION TREATMENT METHODS | |
MA51678A (en) | MUSCLE AMYOTROPHY TREATMENT METHODS |